BREAST CANCER

Sara Hurvitz, MD, discusses VIKTORIA-1 data on gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer, following the drug's recent FDA approval.

Erika Hamilton, MD, discusses HER2CLIMB-05 data showing tucatinib plus HP maintenance extends PFS in HER2+ breast cancer, including brain metastases.

NCCN now prefers gedatolisib plus fulvestrant, with or without palbociclib, for PIK3CA wild-type HR+/HER2– metastatic breast cancer after endocrine therapy.

Digital app-based therapy helps breast cancer survivors cut anxiety over 12 months, while depression gains lag; coaching boosts early use.

WinPro trial shows adding micronized progesterone to pre-surgery letrozole fails to boost Ki67 suppression in ER+/PR+ breast cancer, but may ease hot flushes.

OSU researchers use youth-shaped, AI-assisted messaging to raise young women's awareness that alcohol increases breast cancer risk, testing real change.

Dr Erica Stringer-Reasor of UAB discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next in HR+/HER2– breast cancer care.

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

During a live event, Ruta Rao, MD, and participants discussed how the redefined HER2 spectrum is reshaping first antibody-drug conjugate selection in HR+/HER2– metastatic breast cancer.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks drinking habits.

Five-year WSG TP-II results suggest chemo-free endocrine therapy with dual HER2 blockade matches paclitaxel, with fewer severe side effects.

INVINCIBLE-4 restarts testing intratumoral INT230-6 before neoadjuvant pembrolizumab chemotherapy in early TNBC, aiming to boost pCR while reducing severe adverse effects.

National BRFSS study reveals SOGI adults lag in cervical and breast cancer screening; gaps are linked to insurance, access, and stigma.

Phase 3 VIKTORIA-1 results show that gedatolisib combinations extend progression-free survival in PIK3CA-mutated breast cancer, with strong response rates and manageable stomatitis.

Eating flavonoid-rich foods such as apples, oranges, and berries is linked to lower breast cancer risk, with the biggest benefit seen in women with high genetic risk.

New study shows breast cancers within 3 years post partum score higher on Oncotype DX, reshaping risk window and treatment decisions.

KEYNOTE-355 suggests responders can pause chemo yet maintain survival on pembrolizumab; immune side effects are mostly mild and manageable.

Data link food deserts to metastatic breast cancer mutations and shorter survival, urging oncologists to screen for food insecurity.

ASCO 2026 highlights, FDA moves, and AI mammography sharpen breast cancer care—ADCs, ctDNA, and de-escalation reshape treatment and screening debates.

MammaPrint in the FLEX registry predicts which HR+/HER2– early breast cancers benefit from anthracyclines—guiding safer, personalized chemo.

Myriad’s Precise MRD expands to breast, colorectal and renal cancers, using serial ctDNA tracking to spot residual disease and predict response.

FDA approves sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for unresectable/metastatic triple-negative breast cancer.

FDA approves palbociclib plus trastuzumab, with/without pertuzumab, and endocrine therapy as maintenance for HR+, HER2+ advanced breast cancer.

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.